Science PolicyAgingNeurological and Psychiatric Disorders Sarah Wade April 4, 2023April 4, 2023 aducanumab, Alzeihmer's disease, amyloid-β plaques, clinical trials, CMS, Cognitive Decline, donanemab, FDA, lecanemab, Science Policy, Tau FDA Under Scrutiny: A Tale of Two Drugs By Sarah Wade Alzheimer’s disease (AD) is a devastating illness that gradually destroys the brain. This disease affects over 30 million people worldwide (Haque & Levey, 2019) and is the… Read More
